BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-28@catalystbrief.girapphe.com
DTSTAMP:20261117T061547Z
LAST-MODIFIED:20261117T061547Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: AbbVie — Risankizumab SC [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Assess Adverse Events an
 d Change in Disease Activity of Risankizumab Subcutaneous Induction Treatm
 ent for Moderately to Severely Active Crohn's Disease..\nSource: https://c
 linicaltrials.gov/study/NCT06063967\nhttps://catalystbrief.girapphe.com/e/
 28?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/28?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
